Drug Approval | July 02, 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer
Imfinzi also recommended for patients with mismatch repair deficient disease
Imfinzi also recommended for patients with mismatch repair deficient disease
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Renews GMP certifications for India and Malaysia sites
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Subscribe To Our Newsletter & Stay Updated
